Omega Healthcare Investors, Inc. Releases Financial Results for Q4 2024

On February 5, 2025, Omega Healthcare Investors, Inc. (NYSE: OHI) disclosed its financial outcomes for the quarter and year concluding December 31, 2024. The company’s fourth-quarter and annual highlights showcased a significant growth trajectory compared to the previous corresponding periods.

In the fourth quarter of 2024, Omega reported a net income of $116 million, reflecting $0.41 per common share, as compared to $57 million and $0.22 per common share in Q4 2023. Nareit Funds From Operations (“Nareit FFO”) saw an increase to $196 million, or $0.68 per common share, compared to $129 million and $0.50 per common share during the same period in 2023. Adjusted Funds From Operations (“Adjusted FFO” or “AFFO”) also showed growth, standing at $214 million, or $0.74 per common share, as opposed to $173 million and $0.68 per common share in Q4 2023. Funds Available for Distribution (“FAD”) for the quarter summed up to $202 million, or $0.70 per common share, in contrast to $163 million and $0.64 per common share during the corresponding period in 2023.

Throughout Q4 2024, Omega finalized approximately $340 million in new investments, covering $179 million in real estate acquisitions and $162 million in real estate loans. Additionally, the company issued 11 million common shares, garnering gross proceeds of $438 million during the quarter.

The company not only showcased a robust fourth quarter but also strong performance for the full year 2024. Net income for 2024 amounted to $418 million, equivalent to $1.55 per common share, compared to $249 million and $1.00 per common share in 2023. Nareit FFO reported $734 million, or $2.71 per common share, compared to $591 million and $2.36 per common share in 2023. AFFO for 2024 demonstrated an increase to $778 million, or $2.87 per common share, in contrast to $699 million and $2.79 per common share in 2023.

Omega’s outlook for 2025 includes an Adjusted FFO range of $2.90 to $2.98 per diluted share. The guidance accounts for various factors, such as completed acquisitions in 2024, assumes specific expense levels, repayment of debts, and balance sheet cash estimates by December 31, 2025.

CEO Taylor Pickett expressed satisfaction with the company’s performance, highlighting an increase in FAD per share and ongoing efforts to strengthen the balance sheet. With a positive operating landscape and an active investment pipeline, Omega remains optimistic about its future prospects despite potential regulatory changes in the healthcare industry.

Omega’s financial results are available in detail in the Fourth Quarter 2024 Financial Supplemental on the company’s website. Investors and analysts can delve deeper into the company’s performance during the conference call scheduled for February 6, 2025, to discuss the Q4 results and current developments. This call will provide insights into Omega’s strategic initiatives and financial standing in the evolving healthcare real estate sector.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Omega Healthcare Investors’s 8K filing here.

Omega Healthcare Investors Company Profile

Omega Healthcare Investors, Inc engages in the provision of financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities, assisted living facilities, independent living facilities, rehabilitation and acute care facilities, and medical office buildings.